Pila Pharma AB (publ) (STO:PILA)

Market Cap	65.78M -25.8%
Revenue (ttm)	1.13M +42.6%
Net Income	-17.00M
EPS	-0.49
Shares Out	45.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,979
Open	1.410
Previous Close	1.425
Day's Range	1.410 - 1.440
52-Week Range	1.024 - 3.930
Beta	-0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PILA

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.65% compared to the previous year's 789,889. Losses were -17.00 million, 51.3% more than in 2024.